Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05545969
Title Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia
Age Groups: adult | senior
Covered Countries AUS

No variant requirements are available.